Paul H. Naylor

2.5k total citations
104 papers, 1.9k citations indexed

About

Paul H. Naylor is a scholar working on Immunology, Epidemiology and Molecular Biology. According to data from OpenAlex, Paul H. Naylor has authored 104 papers receiving a total of 1.9k indexed citations (citations by other indexed papers that have themselves been cited), including 36 papers in Immunology, 25 papers in Epidemiology and 22 papers in Molecular Biology. Recurrent topics in Paul H. Naylor's work include Hepatitis C virus research (19 papers), Cellular Mechanics and Interactions (16 papers) and Hepatitis B Virus Studies (12 papers). Paul H. Naylor is often cited by papers focused on Hepatitis C virus research (19 papers), Cellular Mechanics and Interactions (16 papers) and Hepatitis B Virus Studies (12 papers). Paul H. Naylor collaborates with scholars based in United States, France and United Kingdom. Paul H. Naylor's co-authors include Allan L. Goldstein, Teresa L. K. Low, Gary B. Thurman, John E. McClure, A L Goldstein, Milton G. Mutchnick, Richard Weindruch, R. L. Walford, Prem S. Sarin and Jeffrey L. Rossio and has published in prestigious journals such as Science, Proceedings of the National Academy of Sciences and Journal of Biological Chemistry.

In The Last Decade

Paul H. Naylor

100 papers receiving 1.8k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Paul H. Naylor United States 23 601 542 322 292 273 104 1.9k
Grazyna Faure France 30 354 0.6× 1.2k 2.3× 212 0.7× 192 0.7× 238 0.9× 76 2.4k
Pilar Lucas Spain 18 635 1.1× 643 1.2× 220 0.7× 99 0.3× 497 1.8× 39 1.6k
John L. Foster United States 24 552 0.9× 781 1.4× 233 0.7× 125 0.4× 787 2.9× 39 1.9k
Carlo Ramoni Italy 28 1.1k 1.8× 1.1k 2.1× 197 0.6× 144 0.5× 257 0.9× 44 2.5k
J Uriel France 25 225 0.4× 823 1.5× 235 0.7× 165 0.6× 67 0.2× 83 1.9k
A Senik France 27 1.6k 2.7× 1.2k 2.1× 538 1.7× 152 0.5× 112 0.4× 80 3.2k
Apurva Sarin India 31 1.4k 2.3× 1.6k 3.0× 371 1.2× 259 0.9× 273 1.0× 61 3.0k
Tzvete Dentchev United States 28 695 1.2× 1.0k 1.9× 261 0.8× 121 0.4× 202 0.7× 44 2.3k
Peter Dickie Canada 24 710 1.2× 1.1k 2.0× 228 0.7× 324 1.1× 559 2.0× 38 2.6k
Christelle Borel Switzerland 27 353 0.6× 1.6k 2.9× 329 1.0× 156 0.5× 232 0.8× 50 2.8k

Countries citing papers authored by Paul H. Naylor

Since Specialization
Citations

This map shows the geographic impact of Paul H. Naylor's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Paul H. Naylor with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Paul H. Naylor more than expected).

Fields of papers citing papers by Paul H. Naylor

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Paul H. Naylor. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Paul H. Naylor. The network helps show where Paul H. Naylor may publish in the future.

Co-authorship network of co-authors of Paul H. Naylor

This figure shows the co-authorship network connecting the top 25 collaborators of Paul H. Naylor. A scholar is included among the top collaborators of Paul H. Naylor based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Paul H. Naylor. Paul H. Naylor is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Itani, Mohamad I., et al.. (2024). Impact of DAA Treatment for HCV on Hepatocellular Carcinoma in a Predominately African American Population. Journal of Gastrointestinal Cancer. 55(3). 1324–1332. 2 indexed citations
3.
Naylor, Paul H., et al.. (2023). Racial Disparity in HCV Demographics and Treatment Between Interferon Era (2002–2003) and Direct Acting Anti-viral Era (2019). Cureus. 15(3). e36643–e36643. 1 indexed citations
4.
Naylor, Paul H., et al.. (2019). Racial Diversity in Hepatocellular Carcinoma in a Predominately African-American Population at an Urban Medical Center. Journal of Gastrointestinal Cancer. 51(3). 972–979. 2 indexed citations
5.
Naylor, Paul H. & Milton G. Mutchnick. (2017). Immunotherapy for hepatitis B in the direct acting antiviral era: Reevaluating the thymosin α1 efficacy trials in the light of a combination therapy approach. Journal of Viral Hepatitis. 25(1). 4–9. 16 indexed citations
6.
Naylor, Paul H., et al.. (2016). Overestimate of Fibrosis by FIBROSpect® II in African Americans Complicates the Management of their Chronic Hepatitis C. Journal of Clinical and Translational Hepatology. 4(1). 12–19. 2 indexed citations
7.
Silva, Diane M. Da, Andrew W. Woodham, Paul H. Naylor, et al.. (2015). Immunostimulatory Activity of the Cytokine-Based Biologic, IRX-2, on Human Papillomavirus-Exposed Langerhans Cells. Journal of Interferon & Cytokine Research. 36(5). 291–301. 8 indexed citations
8.
Reddy, Naveen A., et al.. (2015). Effect of Treatment for CHC on Liver Disease Progression and Hepatocellular Carcinoma Development in African Americans. Journal of Clinical and Translational Hepatology. 3(3). 163–168. 5 indexed citations
9.
Naylor, Paul H., et al.. (2007). Immunopharmacology of Thymosin α1 and Cytokine Synergy. Annals of the New York Academy of Sciences. 1112(1). 235–244. 15 indexed citations
10.
11.
Sarin, Prem S., Paul H. Naylor, Jeffrey Kahn, et al.. (1994). Cytotoxic and humoral immune responses to HIV-1 p17 synthetic peptide HGP-30 in human volunteers. 3(1). 49–57. 1 indexed citations
12.
Moscinski, Lynn C., et al.. (1993). Thymosin β4 synergizes with human granulocyte-macrophage colony-stimulating factor in maintaining bone marrow proliferation. Immunopharmacology. 26(1). 83–92. 10 indexed citations
13.
Stryker, Richard, et al.. (1992). A Phase I Study of HGP-30, a 30 Amino Acid Subunit of the Human Immunodeficiency Virus (HIV) p17 Synthetic Peptide Analogue Sub-unit Vaccine in Seronegative Subjects. AIDS Research and Human Retroviruses. 8(8). 1321–1325. 18 indexed citations
14.
Sherman, Kenneth E., et al.. (1991). Low Thymosin Alpha-1 Concentrations in Patients Chronically Infected with the Hepatitis B Virus*. Viral Immunology. 4(3). 195–199. 22 indexed citations
15.
Tryphonas, Helen, M I Luster, Kimber L. White, et al.. (1991). Effects of PCB (aroclor® 1254) on non-specific immune parameters in rhesus (Macaca mulatta) monkeys. International Journal of Immunopharmacology. 13(6). 639–648. 44 indexed citations
16.
Hsia, Judith, Marcelo B. Sztein, Paul H. Naylor, et al.. (1989). Modulation of thymosin alpha 1 and thymosin beta 4 levels and peripheral blood mononuclear cell subsets during experimental rhinovirus colds.. PubMed. 8(4). 383–91. 15 indexed citations
17.
Goldstein, Allan L., et al.. (1988). Enzyme immunoassay measurement of thymosin beta 4 in human serum.. PubMed. 7(1). 91–6. 16 indexed citations
18.
Naz, Rajesh K., Paul H. Naylor, & Goldstein Al. (1987). Thymosin alpha 1 levels in human seminal plasma and follicular fluid: implication in germ cell function.. PubMed. 32(5). 375–9. 7 indexed citations
19.
Goldstein, Allan L., Paul H. Naylor, Richard S. Schulof, et al.. (1985). Thymosin in the Staging and Treatment of HLTV-III Positive Homosexuals and Hemophiliacs with AIDS-Related Immune Dysfunction. Advances in experimental medicine and biology. 187. 129–140. 9 indexed citations
20.
Naylor, Paul H. & Allan L. Goldstein. (1983). Abnormally elevated thymosin α1 levels in the acquired immunodeficiency syndrome (AIDS). Clinical Immunology Newsletter. 4(9). 126–128. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Grazyna Faure Breakdown of academic impact, for papers by Pilar Lucas Breakdown of academic impact, for papers by John L. Foster Breakdown of academic impact, for papers by Carlo Ramoni Breakdown of academic impact, for papers by J Uriel Breakdown of academic impact, for papers by A Senik Breakdown of academic impact, for papers by Apurva Sarin Breakdown of academic impact, for papers by Tzvete Dentchev Breakdown of academic impact, for papers by Peter Dickie Breakdown of academic impact, for papers by Christelle Borel
Rankless by CCL
2026